About Epstein-Barr Virus (EBV) Research
Epstein-Barr virus (EBV), a member of the herpes virus family, is the most common cause of infectious mononucleosis (IM), generally known as mono. Sometimes referred to as the kissing disease, mononucleosis spreads easily through saliva and occurs primarily in adolescents and young adults. Most people will be infected with EBV in their lifetime. Prior EBV infection may also be linked to a few cancers, including Hodgkin’s, non-Hodgkin’s, and Burkitt’s lymphoma, and increases the risk of nasopharyngeal carcinoma. It is estimated that about 200,000 new cancer diagnoses are a result of EBV infection each year.
An EBV vaccine could be a crucial preventive measure to mitigate the burden of EBV-related diseases, potentially protecting a large portion of the population and significantly improving health outcomes for all.
Why Participate
You can help advance medicine by joining a clinical trial at Velocity, and you may also:
- Learn about potential new medicines in development
- Get study-related medical exams at no cost
- Receive compensation for participating (available amounts may differ for each study)
After you submit your information, a Velocity enrollment specialist will contact you. Together, we’ll review studies that might be right for you and answer your questions.
Health insurance is NOT required to join. There is never an obligation to participate — we’re here to help you make the best decision.
For more information about currently enrolling research studies, complete the form on this page or select a location below to get in touch with a Velocity enrollment specialist.
